Brolucizumab-Dbll vs Surabgene lomparvovec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

Surabgene lomparvovec

Developed by AbbVie and partners

Phase 3 in Age-Related Macular DegenerationAAV gene therapy
Weak signal

NCT04832724 · Phase 2 · completed

The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.

Next expected readout: December 2026 · NCT04704921 (registry estimate)

Reported efficacy

RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)

Result source: NCT04832724

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Surabgene lomparvovec

BCVA Change Letters -7.6 ETDRS letters @ 106wk
absolute change · ETDRS letters
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
1.2 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
14 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0.9 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-3.8 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CRT Change Microns -88.6 m @ 106wk
absolute change · m
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
25.3 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-56.7 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-108.2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Supplemental Injection Rate Annualized 10.3 per year @ 106wk
event rate · per year
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
9.3 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2.8 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
4.4 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CNV Area Change Mm2 -0.4 mm @ 106wk
absolute change · mm
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.2 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.1 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-0.6 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Available safety results

Surabgene lomparvovec

Dropout rate
16.7%Cohort 1
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
8.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—Cohort 1
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
—Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Serious AEs
33.3%Cohort 1
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
33.3%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
25%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
33.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
intraocular inflammation 66.7%
retinal haemorrhage 66.7%
visual acuity reduced/impairment 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
conjunctival haemorrhage 50%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 66.7%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100%
conjunctival haemorrhage 75%
retinal thickening 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 91.7%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7%
eye irritation 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · Surabgene lomparvovec's landscape